Compare Citius Pharmaceuticals Inc (CTXR) vs H2O America (HTO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs H2O America — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while H2O America trades at $58.67 (market cap $2.43B). The key difference: H2O America is far larger — about 178.4× Citius Pharmaceuticals Inc's market cap, and H2O America pays a 3.03% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and H2O America for 40 Days on average.
| CTXR | HTO | |
|---|---|---|
Market Cap | $13.62M | $2.43B |
Volume | 132,438 | 593,883 |
Sector | Health | Utilities |
52-Week High | $1.82 | $65.43 |
52-Week Low | $0.48 | $44.44 |
Typical Hold Time | 16 Days | 40 Days |
Enterprise Value | $3.79M | $4.22B |
Dividend Yield | — | 3.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
HTO trades at $57.98, down 0.34% with a bearish technical signal despite recent earnings beats. The company maintains strong profitability with 12.91% net margin and 6.46% ROE, supported by recent acquisitions in Texas water utilities. Analyst consensus remains strongly bullish with 83% buy ratings and $66.50 price target, representing 15% upside potential from current levels.
The stock offers attractive dividend yield with recent $0.44 dividend declaration, but faces execution risks from acquisition integration and negative cash flow from investing activities. Technical indicators show mixed signals with oversold RSI readings conflicting with bearish moving averages, creating potential entry opportunity for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About H2O America
H2O America is a utility company that provides essential water and wastewater services, primarily in the United States. The company operates a network of regulated water and wastewater systems, focusing on responsible resource management and high-quality service delivery. HTO aims to expand its operational footprint through acquisitions and internal growth, serving residential, commercial, and industrial customers.
Read more on HTO →
